ArticleERJ open research2024

Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.

Francesca A Mercuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.